



Resmetirom Prior Authorization with Quantity Limit Program Summary

POLICY REVIEW CYCLE

Effective Date

03-15-2026

Date of Origin

POLICY AGENT SUMMARY PRIOR AUTHORIZATION

Target Brand Agent(s)	Target Generic Agent(s)	Strength	Targeted MSC	Available MSC	Final Age Limit	Preferred Status
Rezdiffra	resmetirom	100 MG ; 60 MG ; 80 MG	M ; N ; O ; Y	N		

POLICY AGENT SUMMARY QUANTITY LIMIT

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist
Rezdiffra	resmetirom	60 MG	30	Tablets	30	DAYS			
Rezdiffra	resmetirom	80 MG	30	Tablets	30	DAYS			
Rezdiffra	resmetirom	100 MG	30	Tablets	30	DAYS			

CLIENT SUMMARY – PRIOR AUTHORIZATION

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Rezdiffra	resmetirom	100 MG ; 60 MG ; 80 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; IL HIM Annual 2025 ; IL HIM Annual 2026 ; IL HMO Performance Quarterly ; IL non-HMO Performance Full ; Jade ; MT Performance Full ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance Full ; OK Performance Full ; Performance ; Performance Annual ; Performance Annual PY ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; TX HIM Annual 2025 ; TX HIM Annual 2026 ; Topaz ; Whole Foods

CLIENT SUMMARY – QUANTITY LIMITS

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Rezdiffra	resmetirom	100 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; IL HIM Annual 2025 ; IL HIM Annual 2026 ; IL HMO Performance Quarterly ; IL non-HMO Performance Full ; Jade ; MT Performance Full ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance Full ; OK Performance Full ; Performance ; Performance Annual ; Performance Annual PY ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; TX HIM Annual 2025 ; TX HIM Annual 2026 ; Topaz ; Whole Foods
Rezdiffra	resmetirom	60 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; IL HIM Annual 2025 ; IL HIM Annual 2026 ; IL HMO Performance Quarterly ; IL non-HMO Performance Full ; Jade ; MT Performance Full ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance Full ; OK Performance Full ; Performance ; Performance Annual ; Performance Annual PY ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; TX HIM Annual 2025 ; TX HIM Annual 2026 ; Topaz ; Whole Foods
Rezdiffra	resmetirom	80 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; IL HIM Annual 2025 ; IL HIM Annual 2026 ; IL HMO Performance Quarterly ; IL non-HMO Performance Full ; Jade ; MT Performance Full ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance Full ; OK Performance Full ; Performance ; Performance Annual ; Performance Annual PY ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; TX HIM Annual 2025 ; TX HIM Annual 2026 ; Topaz ; Whole Foods

PRIOR AUTHORIZATION CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
PA	<p>Initial Evaluation</p> <p>Target Agent(s) will be approved when ALL the following are met:</p> <ol style="list-style-type: none"> 1. ONE of the following: <ol style="list-style-type: none"> A. ALL of the following: <ol style="list-style-type: none"> 1. The patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) (medical records required) AND 2. The patient has stage F2 or F3 fibrosis as confirmed by ONE of the following (prior to therapy with the requested agent): (medical records required) <ol style="list-style-type: none"> A. A liver biopsy within the past 2 years OR B. Vibration-controlled transient elastography (VCTE) OR C. Enhanced liver fibrosis (ELF) score OR D. Magnetic resonance elastography (MRE) AND 3. ONE of the following: <ol style="list-style-type: none"> A. The request is for a BCBS IL Fully Insured, ASO Cost/BBF, HIM, or Non-ERISA ASO/Self-insured Municipalities/Counties member OR B. The patient is currently being treated with the requested agent and the patient is currently stable on the requested agent [chart notes required] OR C. The patient has a BMI less than or equal to 23 kg/m² if the patient is of South Asian, Southeast Asian, or East Asian descent (medical records required) OR D. The patient has BMI less than or equal to 25 kg/m² (medical records required) OR E. The patient has tried and had an inadequate response after 72 weeks of therapy with Wegovy [chart notes required] OR F. The patient has tried and had an inadequate response after 72 weeks of therapy with another subcutaneous GLP-1 agent for the treatment of the requested indication [chart notes required] OR G. A subcutaneous GLP-1 agent for the treatment of the requested indication was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event [chart notes required] OR H. The patient has an intolerance or hypersensitivity to therapy with Wegovy [chart notes required] OR I. The patient has an FDA labeled contraindication to Wegovy [chart notes required] OR J. Wegovy is expected to be ineffective based on the known clinical characteristics of the patient and the known characteristics of the prescription drug; OR cause a significant barrier to the patient's adherence of care; OR worsen a comorbid condition; OR decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities; OR cause an adverse reaction or cause physical or mental harm [chart notes required] OR K. Wegovy is not in the best interest of the patient based on medical necessity [chart notes required] OR L. The patient has tried another prescription drug in the same pharmacologic class or with the same mechanism of action as Wegovy and that prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event [chart notes required] AND 4. ONE of the following: <ol style="list-style-type: none"> A. If the patient's sex is female then the patient's alcohol consumption is less than 20 grams/day (Note: one standard

Module	Clinical Criteria for Approval
	<p>alcoholic drink contains roughly 14 grams of pure alcohol, which is found in 12 ounces of regular beer, 5 ounces of wine, or 1.5 ounces of distilled spirits) (medical records required) OR</p> <p>B. If the patient's sex is male then the patient's alcohol consumption is less than 30 grams/day (Note: one standard alcoholic drink contains roughly 14 grams of pure alcohol, which is found in 12 ounces of regular beer, 5 ounces of wine, or 1.5 ounces of distilled spirits) (medical records required) AND</p> <p>5. The patient is being monitored and/or treated for any comorbid conditions (e.g., cardiovascular disease, diabetes, dyslipidemia, hypertension) AND</p> <p>6. BOTH of the following:</p> <p>A. The patient is currently on a weight management regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND</p> <p>B. The patient will continue the weight management regimen in combination with the requested agent OR</p> <p>B. The patient has another FDA labeled indication for the requested agent AND</p> <p>2. If the patient has an FDA labeled indication, then ONE of the following:</p> <p>A. The patient's age is within FDA labeling for the requested indication for the requested agent OR</p> <p>B. There is support for using the requested agent for the patient's age for the requested indication AND</p> <p>3. The patient does NOT have ANY of the following: (medical records required)</p> <p>A. Decompensated cirrhosis</p> <p>B. Moderate to severe hepatic impairment (Child-Pugh Class B or C)</p> <p>C. Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis) AND</p> <p>4. The prescriber is a specialist in the area of the patient's diagnosis (e.g., hepatologist, gastroenterologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND</p> <p>5. The patient does NOT have any FDA labeled contraindications to the requested agent</p> <p>Length of Approval:</p> <p>BCBSOK: 36 months</p> <p>ALL other plans: 12 months</p> <p>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria.</p> <p>The requested agent will also be approved when ONE of the following is met:</p> <p>1. The request is for a BCBS NM Fully Insured or NM HIM member and ALL of the following:</p> <p>A. The patient does NOT have any FDA labeled contraindications to the requested agent AND</p> <p>B. The requested indication is a rare disease AND</p> <p>C. ONE of the following:</p> <p>1. The patient has another FDA labeled indication for the requested agent and route of administration OR</p> <p>2. The patient has another indication that is supported in compendia for the requested agent and route of administration OR</p> <p>2. ALL of the following:</p> <p>A. The member resides in Ohio AND</p> <p>B. The plan is Fully Insured or HIM Shop (SG) AND</p> <p>C. The patient does NOT have any FDA labeled contraindications to the requested agent AND</p> <p>D. ONE of the following:</p>

Module	Clinical Criteria for Approval
	<ol style="list-style-type: none"> 1. The patient has another FDA labeled indication for the requested agent and route of administration OR 2. The patient has another indication that is supported in compendia for the requested agent and route of administration OR 3. The prescriber has submitted TWO articles from major peer-reviewed professional medical journals [e.g., Journal of American Medical Association (JAMA), New England Journal of Medicine (NEJM), Lancet] supporting the proposed use(s) as generally safe and effective. Accepted study designs may include, but are not limited to, randomized, double blind, placebo controlled clinical trials. NOTE: Case studies are not acceptable [journal articles required] <p>Non-oncology compendia allowed: DrugDex level 1, 2A or 2B, AHFS-DI (narrative text must be supportive)</p> <p>Oncology compendia allowed: NCCN 1 or 2A, AHFS-DI (narrative text must be supportive), DrugDex level 1, 2A, or 2B, or Clinical Pharmacology (narrative text must be supportive), Lexi-Drugs evidence level A, peer-reviewed medical literature</p> <p>Length of Approval:</p> <p>BCBSOK: 36 months</p> <p>ALL other plans: 12 months</p> <p>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria.</p> <p>Renewal Evaluation</p> <p>Target Agent(s) will be approved when ALL of the following are met:</p> <ol style="list-style-type: none"> 1. The patient has been previously approved for the requested agent through the plan's Prior Authorization process (Note: patients not previously approved for the requested agent will require initial evaluation review) AND 2. ONE of the following: <ol style="list-style-type: none"> A. The patient has a diagnosis of noncirrhotic nonalcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH) (medical records required) AND <ol style="list-style-type: none"> 1. ONE of the following: <ol style="list-style-type: none"> A. If the patient's sex is female then the patient's alcohol consumption is less than 20 grams/day (Note: one standard alcoholic drink contains roughly 14 grams of pure alcohol, which is found in 12 ounces of regular beer, 5 ounces of wine, or 1.5 ounces of distilled spirits) (medical records required) OR B. If the patient's sex is male then the patient's alcohol consumption is less than 30 grams/day (Note: one standard alcoholic drink contains roughly 14 grams of pure alcohol, which is found in 12 ounces of regular beer, 5 ounces of wine, or 1.5 ounces of distilled spirits) (medical records required) AND 2. BOTH of the following: <ol style="list-style-type: none"> A. The patient is currently on a weight management regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND B. The patient will continue the weight management regimen in combination with the requested agent OR B. The patient has a diagnosis other than noncirrhotic nonalcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH) AND

Module	Clinical Criteria for Approval
	<p>3. The patient has had clinical benefit with the requested agent AND</p> <p>4. The patient does NOT have ANY of the following: (medical records required)</p> <ul style="list-style-type: none"> A. Decompensated cirrhosis B. Moderate to severe hepatic impairment (Child-Pugh Class B or C) C. Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis) AND <p>5. The prescriber is a specialist in the area of the patient's diagnosis (e.g., hepatologist, gastroenterologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis AND</p> <p>6. The patient does NOT have any FDA labeled contraindications to the requested agent</p> <p>Length of Approval:</p> <p>BCBSOK: 36 months</p> <p>ALL other plans: 12 months</p> <p>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria.</p>

QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
	<p>Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:</p> <ul style="list-style-type: none"> 1. The requested quantity (dose) does NOT exceed the program quantity limit OR 2. The requested quantity (dose) exceeds the program quantity limit AND ONE of the following: <ul style="list-style-type: none"> A. BOTH of the following: <ul style="list-style-type: none"> 1. The requested agent does NOT have a maximum FDA labeled dose for the requested indication AND 2. There is support for therapy with a higher dose for the requested indication OR B. BOTH of the following: <ul style="list-style-type: none"> 1. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND 2. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit <p>Length of Approval: 12 months</p>